Bioson Pharmaceutical succeeded in achieving high revenue growth and profitability in the third quarter, driven by strong growth in the ethical drugs (ETC) sector.
On the 14th, Bioson Pharmaceutical announced that its consolidated sales for the third quarter of this year reached 23.6 billion KRW, and operating profit was 1.3 billion KRW, representing increases of 32.2% and 13.3% respectively compared to the same period last year. Net profit for the same period was recorded at 300 million KRW.
The strong performance of the ETC division, the company's core business area, led the significant revenue growth in the third quarter following the second quarter. ETC sales surged 47.1% year-on-year to 14.4 billion KRW. Additionally, contract manufacturing organization (CMO) and over-the-counter (OTC) products also showed steady growth compared to the previous year, contributing to the overall performance increase.
By product, sales of the gastric ulcer treatment ‘Alzatin Capsule 150 milligrams (mg)’ increased by more than 250%. The proactive response to the impurity detection controversy in nizatidine formulations and enhanced safety measures differentiated the product from competitors, proving effective. The erectile dysfunction treatment ‘Vigra Tablets 50·100 mg (active ingredient sildenafil citrate)’, launched in August, surpassed 100 million KRW in sales within two months of release, standing out in the erectile dysfunction treatment market.
A representative from Bioson Pharmaceutical stated, "We are showing high growth this year centered on ETC through strengthened sales capabilities and product line expansion. We will continue to focus on enhancing competitiveness to drive revenue growth and profitability."
He added, "With a stable performance base secured, we are concentrating on obtaining product approval and preparing marketing for the non-narcotic analgesic Opiranserin (product name Anapraju)."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
